JonesTrading analyst Justin Walsh maintained a Buy rating on Plus Therapeutics (PSTV – Research Report) today and set a price target of $5.00. The company’s shares closed last Friday at $0.26.
Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Theratechnologies, and Mainz Biomed B.V.. According to TipRanks, Walsh has an average return of -22.0% and a 31.33% success rate on recommended stocks.
Currently, the analyst consensus on Plus Therapeutics is a Strong Buy with an average price target of $3.80, representing a 1,339.39% upside. In a report released on April 21, H.C. Wainwright also maintained a Buy rating on the stock with a $3.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Plus Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.81 million. In comparison, last year the company had a GAAP net loss of $4.12 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing scale up of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. The lead drug product candidate in pipeline, DocePLUS™, is being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, and other professionals. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
Read More on PSTV:
- Plus Therapeutics reports Q1 EPS (14c), consensus (13c)
- Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
- Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
- Plus Therapeutics completes enrollment in Cohort 8 of ReSPECT-GBM Phase 1/2a
- Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference
